Hemophilia Gene Therapy Market - Size, Share, Trends, and Forecast, 2022 - 2028

Hemophilia Gene Therapy Market - Size, Share, Trends, and Forecast, 2022 - 2028

Hemophilia is a genetic disorder in which patient’s blood do not clot normally due to lack of blood-clotting proteins known as coagulating factors. Conventional treatment options include timely replacement of the specific clotting factor. Major pharma and biotech companies are conducting research and development to develop gene therapy for hemophilia due to various shortcomings with conventional therapy. Increasing number of hemophilic patients that require treatment and strong product pipeline are expected to drive growth of the hemophilia gene therapy market.

Market Dynamics

Major factors that are driving growth of the hemophilia gene therapy market include increasing prevalence of hemophilia, issue of high cost, access to current hemophilia treatment, which includes coagulation factor VIII and IX, and increasing number of companies engaged in research and development of gene therapy products. According to the Centers for Disease Control and Prevention, hemophilia A is a rare, X-linked bleeding disorder that affects around 1 in 5,000 to 10,000 live-born males. Hemophilia B is less common than hemophilia A, with an incidence of around 1 in 25,000 births. According to 2016 global survey by the World Federation of Hemophilia, the total number of individuals with hemophilia worldwide was 184,723, including 16,949 within the U.S.
Key features of the study:
This report provides in-depth analysis of the global hemophilia gene therapy market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, pipeline analysis, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global hemophilia gene therapy market based on the following parameters – company overview, financial performance, market presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include BioMarin Pharmaceuticals, Inc., Spark Therapeutics, Pfizer, Inc., UniQure NV, Ultragenyx Pharmaceutical, Shire PLC, Sangamo Therapeutics, Inc., and Freeline Therapeutics
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, product up-gradation, market expansion, and marketing tactics
The global hemophilia gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the hemophilia gene therapy market

Detailed Segmentation:
Global Hemophilia Gene Therapy Market, By Type:
Hemophilia A
Hemophilia B
Global Hemophilia Gene Therapy Market, By Region:
North America
By Type
Hemophilia A
Hemophilia B
By Country:
U.S.
Canada
Latin America
By Type
Hemophilia A
Hemophilia B
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Type
Hemophilia A
Hemophilia B
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Type
Hemophilia A
Hemophilia B
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Type
Hemophilia A
Hemophilia B
By Country:
GCC
Israel
Rest of Middle East
Africa
By Type
Hemophilia A
Hemophilia B
By Country:
South Africa
Central Africa
North Africa
Company Profiles
BioMarin Pharmaceuticals, Inc. *
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategies
Spark Therapeutics
Pfizer, Inc.
UniQure NV
Ultragenyx Pharmaceutical
Shire PLC
Sangamo Therapeutics
Freeline Therapeutics
“*” marked represents similar segmentation in other categories in the respective section.